Acorda Therapeutics Announces Pricing of Initial Public Offering.HAWTHORNE, N.Y. -- Acorda Therapeutics (Nasdaq: ACOR ACOR Association of Cancer Online Resources ACOR American Center of Oriental Research ACOR Advanced Certificate in Operational Risk ACOR Assistant Contracting Officer Representative ACOR Actual Cost of Repair ACOR Administrative Contracting Officers Representative ) announced today the initial public offering of 5,500,000 shares of common stock at a price of $6.00 per share. All of the shares are being offered by Acorda Therapeutics. Acorda's common stock will begin trading today on The NASDAQ National Market under the symbol "ACOR." Banc of America Securities LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control acted as the sole book-runner and lead manager, and Lazard Capital Markets Lazard Capital Markets is a New York-based investment bank founded in 2005 in a spin-off from its parent Lazard. Lazard Capital Markets focuses its activities on equity research, sales and trading; fixed income and convertible bond sales and trading; and securities , Piper Jaffray and SG Cowen & Co. acted as co-managers. Copies of the final prospectus relating to the offering may be obtained from Banc of America Securities LLC, 9 West 57th Street, New York, NY 10019. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Acorda Therapeutics Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis This is a list of people with multiple sclerosis, similar to the category "People with multiple sclerosis" but with sources and explanations. : Top - 0–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z B
Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, is in a Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the improvement of walking ability in persons with multiple sclerosis. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion